ELYM · Eliem Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $46.71M | $14.18M | $15.41M | $26.21M | $8.77M |
| SG&A | $21.17M | $16.02M | $24.86M | $18.92M | $2.42M |
| Total Operating Expenses | $67.88M | $82.02M | $40.27M | $45.13M | $20.93M |
| D&A | $0 | - | - | - | - |
| Operating Income | ($67.88M) | ($82.02M) | ($40.27M) | ($45.13M) | ($20.93M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($59.85M) | ($73.90M) | ($35.12M) | ($45.24M) | ($20.67M) |
| EPS - Basic | ($0.88) | ($1.53) | ($1.30) | ($4.24) | - |
| EPS - Diluted | ($0.88) | ($1.53) | ($1.30) | ($4.24) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $2.27M | $705.0K | $66.0K | $750.0K | $1.40M |
| Current Assets | $105.85M | $154.87M | $110.25M | $134.39M | $148.25M |
| Total Assets | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M |
| Current Liabilities | $6.98M | $4.93M | $2.83M | $6.10M | $6.03M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M |
| Stockholders' Equity | $160.47M | $211.88M | $107.60M | $128.72M | $167.20M |
| Retained Earnings | ($289.73M) | ($229.88M) | ($155.98M) | ($120.86M) | ($75.62M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($54.36M) | ($15.56M) | ($20.60M) | ($37.37M) | ($14.10M) |
| Investing Cash Flow | $2.83M | ($121.09M) | $68.98M | $34.44M | $8.08M |
| Financing Cash Flow | ($21.0K) | $130.73M | $841.0K | $0 | $4.92M |
| CapEx | $0 | $4.64M | - | - | - |
| Free Cash Flow | ($54.36M) | ($20.21M) | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.91 | 0.27 | - | - | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -35.7% | -34.0% | -31.8% | -33.5% | -11.9% |
| Return on equity | -37.3% | -34.9% | -32.6% | -35.2% | -12.4% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 |
| Quick ratio | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 |
| Cash ratio | 5.11 | 17.69 | 32.87 | 7.15 | 7.78 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.05 | 1.03 | 1.03 | 1.05 | 1.04 |
| Liabilities / Assets | 0.04 | 0.02 | 0.03 | 0.05 | 0.03 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 17.2% | -103.6% | 10.8% | -115.7% | - |
| Net income growth (YoY) | 19.0% | -110.4% | 22.4% | -118.9% | - |
| EPS growth (YoY) | 42.5% | -17.7% | 69.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -169.0% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -24.3% | 96.9% | -16.4% | -23.0% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Eliem Therapeutics against the 5 most active filers in the same SIC group.